Cas:22556-62-3 1-oleoyl-sn-glycero-3-phosphate sodium salt manufacturer & supplier

Chemical Name:1-oleoyl-sn-glycero-3-phosphate sodium salt

CAS.NO:22556-62-3

Synonyms:OLEOYL-SN-3-GLYCEROPHOSPHATE SODIUM SALT;18:1 LYSO PA SODIUM SALT;1-oleoyl-sn-glycerol 3-phosphate sodium salt;LYSOPHOSPHATIDIC ACID,SODIUM SALT;1-OLEOYL LYSOPHOSPHATIDIC ACID SODIUM SALT;MFCD00133427;Sodium (2R)-2-hydroxy-3-[(9Z)-9-octadecenoyloxy]propyl hydrogen phosphate;L-A-lysophosphatidic acid;9-Octadecenoic acid, (2R)-2-hydroxy-3-(phosphonooxy)propyl ester, sodium salt, (9Z)- (1:1);OLEOYL-SN-GLYCERO-3-PHOSPHATE SODIUM SALT;L-A-LYSOPHOSPHATIDIC ACID,OLEOYL*SODIUM

Molecular Formula:C₂₁H₄₀NaO₇P

Molecular Weight:458.502

HS Code:

Physical and Chemical Properties:

Melting point:N/A

Boiling point:581.5ºC at 760mmHg

Density:N/A

Index of Refraction:

PSA:125.93000

Exact Mass:458.240936

LogP:5.47550

Material Safety Information (Applicable for Hazard Chemicals)

RIDADR:NONH for all modes of transpor

Packing Group:

Contact us for information like OLEOYL-SN-3-GLYCEROPHOSPHATE SODIUM SALT chemical properties,Structure,melting point,boiling point,density,molecular formula,molecular weight,L-A-LYSOPHOSPHATIDIC ACID,OLEOYL*SODIUM physical properties,toxicity information,customs codes,safety, risk, hazard and MSDS, CAS,cas number,MFCD00133427 Use and application,18:1 LYSO PA SODIUM SALT technical grade,usp/ep/jp grade.

Related News: China’s pharmaceutical CMO market has recently maintained a growth rate of more than 10%. From the perspective of market structure, the average growth rate of clinical production is 9.5%, while the average growth rate of commercial production will reach 18.7%. 1-oleoyl-sn-glycero-3-phosphate sodium salt manufacturer China’s pharmaceutical CMO market has recently maintained a growth rate of more than 10%. From the perspective of market structure, the average growth rate of clinical production is 9.5%, while the average growth rate of commercial production will reach 18.7%. 1-oleoyl-sn-glycero-3-phosphate sodium salt supplier Factors that have a significant impact on the sales volume of APIs come from the production side, which mainly includes costs and processes. 1-oleoyl-sn-glycero-3-phosphate sodium salt vendor The Breakthrough Designation for the iLet Bionic Pancreas System contemplates configurations with most insulin analogs approved for pumping as well as dasiglucagon, Zealand Pharma��s stable pumpable glucagon analog, which has a unique stability profile in a ready-to-use aqueous solution. 1-oleoyl-sn-glycero-3-phosphate sodium salt factory Factors that have a significant impact on the sales volume of APIs come from the production side, which mainly includes costs and processes.